Merrion Pharmaceuticals has filed for an IPO to raise up to $146 million. The company has been developing technology that increases the bioavailability of drugs in the GI tract. Its researchers have been working to develop oral drugs that replace injectables.
- see this press release
- here's the report on the IPO from TechJournal
ALSO: Amicus Therapeutics, which is working on new therapies for genetic diseases, has registered an IPO that is designed to raise $86.25 million. Amicus has raised about $146 million in venture funds, with backers that include New Enterprise Associates, Frazier Healthcare Ventures, Prospect Venture Partners, CHL Medical Partners, Canaan Partners, Quaker BioVenture. Report